Deflazacort in juvenile chronic arthritis.

Journal article

Vertebral crush fracture associated with glucocorticoid therapy causes major morbidity in juvenile chronic arthritis (JCA). Deflazacort (DFZ) may have an advantage over prednisone (PRED) because of its alleged bone sparing properties. Of 34 children with JCA receiving more than 5 mg PRED/day, 31 completed a 1-year, double blind, randomized, comparative trial of DFZ and PRED. Patient characteristics at trial entry were well matched. DFZ and PRED were prescribed in equivalent amounts. DFZ achie...

Expand abstract

Authors: Loftus, J; Reeve, J; Hesp, R; David, J; Ansell, B

• Journal: Journal of rheumatology. Supplement
• Volume: 37
• Pages: 40-42
• Publication date: 1993-04-01
• ISSN: 0380-0903
• Language: English
• Keywords: Humans; Prednisone; Bone Density; Pregnenediones; Anti-Inflammatory Agents; Child; Chronic Disease; Lumbar Vertebrae; Analysis of Variance; Absorptiometry, Photon; Double-Blind Method; Arthritis, Juvenile Rheumatoid; Weight Gain